X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Consumer: Favorable cost scenario props up profits... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

StockSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Aug 12, 2015 - GSK Consumer: Favorable cost scenario props up profits...

GSK Consumer: Favorable cost scenario props up profits...
Aug 12, 2015

GSK Consumer Healthcare declared results for the quarter ended June 2015. The company's revenues were up by 8% YoY, while profits rose by 19% YoY. Here is our analysis of the results:

Performance summary
  • Revenues rise by 8% YoY.
  • Operating profits grow by 21% YoY; margins expand by 2% YoY to 19%.
  • Net profits expand by 19% YoY led by a strong operating performance.

Financial performance summary
(Rs m) 1QFY15 1QFY16 Change
Revenues 9,660 10,450 8.2%
Expenditure 8,013 8,461 5.6%
Operating profit (EBITDA) 1,646 1,989 20.8%
EBITDA margin (%) 17.0% 19.0%  
Other income 458 549 20.0%
Depreciation 119 154 29.1%
Finance cost 2 2 10.5%
Profit before tax 1,983 2,383 20.1%
Tax 682 832 22.1%
Profit after tax/(loss) 1,301 1,550 19.1%
Net profit margin (%) 13.5% 14.8%  
No. of shares (m) 42.1 42.1  
Diluted earnings per share (Rs)*   144.7  
Price to earnings ratio (x)   43.4  
(*On a trailing 12-month basis)

What has driven performance in the quarter ended June 2015?
  • GSK's revenues grew by 8% YoY. As per the company, its 'Horlicks' brand gained market share by 1% during the quarter and continued to maintain its leadership position.

  • Growth would have been higher had it not been for the phase out of excise duty benefits. The south and east regions remain the key markets for the company with the split being 47% and 37% respectively. Exports formed about 6% of the revenues during the quarter. The north and West markets form about 6% and 4% of sales respectively.

  • At the operating level, profits were up by 21% YoY as margins expanded by 2% YoY to 19% led by lower input costs (as a percentage of sales). Net profits grow at similar pace during the quarter.
What to expect?
At the current price of Rs 6,278, GSK trades at a multiple of about 43.4x its trailing twelve month earnings and at about 35x our estimated FY17 EPS.

The company continues to largely focus on marketing & expanding its brand extensions as well as expanding its reach across the country. Rural market expansion is a key focus for the company. The company now has over 13,000 sub distributors, which allow it to reach out to over 200,000 touch points across 27,000 villages. The company is looking to expand its distribution reach and hoping to add 1 m outlets to its network in the next year.

As for our view on the stock, we reiterate that it remains overpriced at the current level and that investors should not buy the stock at this juncture.

To Read the Full Story, Subscribe or Sign In



DISCLOSURES UNDER SEBI (RESEARCH ANALYSTS) REGULATIONS, 2014
INTRODUCTION:
Equitymaster Agora Research Private Limited (hereinafter referred to as "Equitymaster"/"Company") was incorporated on October 25, 2007. Equitymaster is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. Equitymaster is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537.

BUSINESS ACTIVITY:
An independent research initiative, Equitymaster is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes.

DISCIPLINARY HISTORY:
There are no outstanding litigations against the Company, it subsidiaries and its Directors.

GENERAL TERMS AND CONDITIONS FOR RESEARCH REPORT:
For the terms and conditions for research reports click here.

DETAILS OF ASSOCIATES:
Details of Associates are available here.

DISCLOSURE WITH REGARDS TO OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST:
  1. 'subject company' is a company on which a buy/sell/hold view or target price is given/changed in this Research Report
  2. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any financial interest in the subject company.
  3. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have actual/beneficial ownership of one percent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.
  4. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any other material conflict of interest at the time of publication of the research report.
DISCLOSURE WITH REGARDS TO RECEIPT OF COMPENSATION:
  1. Neither Equitymaster nor it's Associates have received any compensation from the subject company in the past twelve months.
  2. Neither Equitymaster nor it's Associates have managed or co-managed public offering of securities for the subject company in the past twelve months.
  3. Neither Equitymaster nor it's Associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
  4. Neither Equitymaster nor it's Associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
  5. Neither Equitymaster nor it's Associates have received any compensation or other benefits from the subject company or third party in connection with the research report.
GENERAL DISCLOSURES:
  1. The Research Analyst has not served as an officer, director or employee of the subject company.
  2. Equitymaster or the Research Analyst has not been engaged in market making activity for the subject company.
Definitions of Terms Used:
  1. Buy recommendation: This means that the investor could consider buying the concerned stock at current market price keeping in mind the tenure and objective of the recommendation service.
  2. Hold recommendation: This means that the investor could consider holding on to the shares of the company until further update and not buy more of the stock at current market price.
  3. Buy at lower price: This means that the investor should wait for some correction in the market price so that the stock can be bought at more attractive valuations keeping in mind the tenure and the objective of the service.
  4. Sell recommendation: This means that the investor could consider selling the stock at current market price keeping in mind the objective of the recommendation service.
Feedback:
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us.

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK CONSUMER SHARE PRICE


Sep 24, 2018 (Close)

TRACK GSK CONSUMER

  • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK CONSUMER 5-YR ANALYSIS

COMPARE GSK CONSUMER WITH

MARKET STATS